Literature DB >> 7679051

Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue.

M E Stearns1, M Wang.   

Abstract

The expression of type IV collagenase (M(r) 72,000) has been examined in tissues from patients with benign prostatic hyperplasia (6 patients) and varying Gleason grades of malignant prostate cancer (18 patients). Immunoperoxidase labeling indicated that expression of the type IV collagenase was weak or nonexistent in benign tissue but consistently strong in the glandular and ductal epithelial cells of prostate tumors diagnosed at Gleason grades 1-8. In moderate to advanced cancer (i.e., Gleason grades 2 to 8), invasive tumor foci in the stromal tissue produced relatively modest amounts of type IV collagenase. The normal stromal tissue (i.e., fibroblasts) uniformly failed to produce detectable levels of type IV collagenase in the 24 patients examined. Northern and quantitative slot blot hybridization assays demonstrated that collagenase type IV mRNA levels were low in benign tissue and high in malignant tumors. In contrast, the stromal cells did not express significant amounts of type IV collagenase mRNA. Enzyme-linked immunosorbent assays demonstrated that the amounts of type IV collagenase protein correlated directly with the mRNA levels in the tumor tissue. The studies suggest that type IV collagenase may be selectively overexpressed by malignant, preinvasive prostatic epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679051

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

1.  Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique.

Authors:  G F Greene; Y Kitadai; C A Pettaway; A C von Eschenbach; C D Bucana; I J Fidler
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 2.  Molecular optical imaging: applications leading to the development of present day therapeutics.

Authors:  Khalid Shah; Ralph Weissleder
Journal:  NeuroRx       Date:  2005-04

3.  Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue.

Authors:  Zhong Dong; R Daniel Bonfil; Sreenivasa Chinni; Xiyun Deng; J Carlos Trindade Filho; Margarida Bernardo; Ulka Vaishampayan; Mingxin Che; Bonnie F Sloane; Shijie Sheng; Rafael Fridman; Michael L Cher
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

Review 4.  Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers.

Authors:  Bal L Lokeshwar
Journal:  Pharmacol Res       Date:  2010-11-18       Impact factor: 7.658

5.  Nanoparticle self-assembly gated by logical proteolytic triggers.

Authors:  Geoffrey von Maltzahn; Todd J Harris; Ji-Ho Park; Dal-Hee Min; Alexander J Schmidt; Michael J Sailor; Sangeeta N Bhatia
Journal:  J Am Chem Soc       Date:  2007-04-21       Impact factor: 15.419

6.  Protease-triggered unveiling of bioactive nanoparticles.

Authors:  Todd J Harris; Geoffrey von Maltzahn; Matthew E Lord; Ji-Ho Park; Amit Agrawal; Dal-Hee Min; Michael J Sailor; Sangeeta N Bhatia
Journal:  Small       Date:  2008-09       Impact factor: 13.281

7.  Fluorescence Molecular Imaging and Tomography of Matrix Metalloproteinase-Activatable Near-Infrared Fluorescence Probe and Image-Guided Orthotopic Glioma Resection.

Authors:  Li Li; Yang Du; Xinjian Chen; Jie Tian
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

8.  Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells.

Authors:  M E Stearns
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

9.  Density-dependent induction of 92-kd type IV collagenase activity in cultures of A431 human epidermoid carcinoma cells.

Authors:  B Xie; C D Bucana; I J Fidler
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

10.  Initial characterization of a dually radiolabeled peptide for simultaneous monitoring of protein targets and enzymatic activity.

Authors:  Efrem Mebrahtu; Alexander Zheleznyak; Minjun A Hur; Richard Laforest; Suzanne E Lapi
Journal:  Nucl Med Biol       Date:  2012-11-12       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.